RU2004116311A - Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции - Google Patents
Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции Download PDFInfo
- Publication number
- RU2004116311A RU2004116311A RU2004116311/04A RU2004116311A RU2004116311A RU 2004116311 A RU2004116311 A RU 2004116311A RU 2004116311/04 A RU2004116311/04 A RU 2004116311/04A RU 2004116311 A RU2004116311 A RU 2004116311A RU 2004116311 A RU2004116311 A RU 2004116311A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- ray diffraction
- diffraction pattern
- addiction
- measured
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Claims (11)
1. Сукцинатная соль 5,8,14-триазатетрацикло-[10.3.1.02,11.04,9]-гексадека-2(11),3,5,7,9-пентаена.
2. Соединение по п.1, где соль является безводной.
3. Соединение по п.2, имеющее рентгеновскую дифрактограмму, характеризуемую, главным образом, наличием пиков на рентгеновской дифрактограмме, как измерено с медным излучателем, при 2θ примерно 13,3 и 17,2.
4. Соединение по п.2, имеющее рентгеновскую дифрактограмму, характеризуемую, главным образом, следующими главными пиками на рентгеновской дифрактограмме, выраженными в терминах 2θ и D-интервалов, как измерено с медным излучателем:
5. Соединение по п.2, отличающееся остановкой перехода плавление/разложение при примерно 198оС.
6. Фармацевтическая композиция, включающая соединение по п.2 и фармацевтически приемлемый носитель.
7. Соединение по п.1, где соль представляет собой гидрат.
8. Соединение по п.7, имеющее рентгеновскую дифрактограмму, характеризуемую, главным образом, наличием пиков на рентгеновской дифрактограмме, как измерено с медным излучателем, при 2θ примерно 13,0, 16,5 и 19,0.
9. Соединение по п.7, имеющее рентгеновскую дифрактограмму, характеризуемую, главным образом, следующими главными пиками на рентгеновской дифрактограмме, выраженными в терминах 2θ и D-интервалов, как измерено с медным излучателем:
10. Способ лечения воспалительных заболеваний кишечника (включая, но не ограничиваясь этим, язвенный колит, гангренозную пиодермию и болезнь Крона), синдрома раздраженной толстой кишки, спастической дистонии, хронических болей, острых болей, нетропической спру (болезнью глютеновой недостаточности), воспаления брюшины, сужения сосудов, беспокойства, панического состояния, депрессии, биполярного расстройства, аутизма, расстройств сна, нарушения суточного ритма организма при перелете через несколько часовых поясов, бокового амиотрофического склероза (БАС), дисфункции познавательной способности, гипертонии, булимии, анорексии, тучности, сердечной аритмии, повышенной кислотности желудка, язвенных болезней, феохромоцитомы, прогрессивной надмышечной атрофии, зависимостей от химических веществ и пристрастия к ним (например, зависимости от или пристрастия к никотину (и/или табачным продуктам), алкоголю, бензодиазепинам, барбитуратам, опиоидам или кокаину), головной боли, мигрени, удара, травматического поражения мозга (ТПМ), обсессивно-компульсивного расстройства (ОКР), психоза, хореи Хантингтона, поздней дискинезии, гиперкинезии, дислексии, шизофрении, мультиинфарктного слабоумия, возрастного ухудшения познавательной способности, эпилепсии, включая эпилепсию кратковременной потери сознания, старческого слабоумия альцгеймеровского типа (болезнь Альцгеймера, БА), болезни Паркинсона (БП), расстройства дефицита внимания - гиперактивности (ADHD), и синдрома Туррета, включающий введение нуждающемуся в лечении субъекту терапевтически эффективного количества соединения по п.1.
11. Способ лечения никотиновой зависимости, пристрастия к никотину и синдрома абстиненции в отношении никотина у млекопитающих, включающий введение нуждающемуся в этом субъекту соединения по п.1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33424501P | 2001-11-29 | 2001-11-29 | |
US60/334,245 | 2001-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2004116311A true RU2004116311A (ru) | 2005-03-27 |
Family
ID=23306297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004116311/04A RU2004116311A (ru) | 2001-11-29 | 2002-10-21 | Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции |
Country Status (26)
Country | Link |
---|---|
US (1) | US6794388B2 (ru) |
EP (1) | EP1461040B1 (ru) |
JP (1) | JP4196829B2 (ru) |
KR (1) | KR20040066140A (ru) |
CN (1) | CN1589148A (ru) |
AR (1) | AR037677A1 (ru) |
AT (1) | ATE320256T1 (ru) |
AU (1) | AU2002341327A1 (ru) |
BR (1) | BR0214559A (ru) |
CA (1) | CA2468705A1 (ru) |
DE (1) | DE60209929T2 (ru) |
DO (1) | DOP2002000512A (ru) |
ES (1) | ES2258652T3 (ru) |
GT (1) | GT200200236A (ru) |
HN (1) | HN2002000332A (ru) |
IL (1) | IL161326A0 (ru) |
MX (1) | MXPA04003192A (ru) |
PA (1) | PA8559401A1 (ru) |
PE (1) | PE20030738A1 (ru) |
PL (1) | PL374325A1 (ru) |
RU (1) | RU2004116311A (ru) |
SV (1) | SV2004001413A (ru) |
TW (1) | TW200300345A (ru) |
UY (1) | UY27548A1 (ru) |
WO (1) | WO2003045394A1 (ru) |
ZA (1) | ZA200402720B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2527970C2 (ru) * | 2008-12-11 | 2014-09-10 | Селл Терапьютикс,Инк. | Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122008000038I1 (de) * | 1997-12-31 | 2008-11-13 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
DK1628685T3 (da) | 2003-04-25 | 2011-03-21 | Gilead Sciences Inc | Antivirale phosphonatanaloge |
WO2004103372A1 (en) * | 2003-05-20 | 2004-12-02 | Pfizer Products Inc. | Pharmaceutical compositions of varenicline |
RU2317295C1 (ru) * | 2003-10-27 | 2008-02-20 | Мерк Энд Ко., Инк. | Соль антагониста ccr-2 |
HUE043207T2 (hu) | 2004-07-27 | 2019-08-28 | Gilead Sciences Inc | HIV-gátló vegyületek foszfonát analógjai |
US20110086086A1 (en) * | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
KR100734147B1 (ko) * | 2005-07-29 | 2007-07-02 | 주식회사 엘지데이콤 | 호 알림 지연을 통한 멀티미디어 통화연결음 서비스 시스템및 방법 |
WO2007136650A2 (en) * | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Method and compositions for treating hematological malignancies |
KR20090086071A (ko) * | 2006-11-09 | 2009-08-10 | 화이자 프로덕츠 인코포레이티드 | 니코틴 중간체의 다형체 |
PT2125786E (pt) * | 2006-12-21 | 2011-04-21 | Pfizer Prod Inc | Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1hpirazol- 3-il)fenoxi)metil)quinolina |
WO2009109651A1 (en) * | 2008-03-06 | 2009-09-11 | Medichem, S.A. | SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE |
CA2709774C (en) | 2008-05-22 | 2012-10-02 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
US20100093667A1 (en) | 2008-07-08 | 2010-04-15 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
WO2010005643A1 (en) * | 2008-07-10 | 2010-01-14 | Teva Pharmaceutical Industries Ltd. | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
US20120093887A1 (en) | 2009-06-10 | 2012-04-19 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
EP2438054A1 (en) | 2009-06-22 | 2012-04-11 | Teva Pharmaceutical Industries Ltd. | Solid states forms of varenicline salts and processes for preparation thereof |
WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
JP5925381B2 (ja) | 2012-04-13 | 2016-05-25 | ▲連雲▼港金康和信▲薬業▼有限公司Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | 化合物[4−(2−アミノ−10−メチル−4−オキソ−6,7,8,9−テトラヒドロ−4a,7−エピミノピリミド[4,5−b][1,4]ジアゼピン−5(4H)−イル)ベンゾイル]−グルタメート及びその製造 |
JP6873906B2 (ja) | 2014-10-20 | 2021-05-19 | オイスター ポイント ファーマ インコーポレイテッド | 眼の病状の治療方法 |
EP3970724A1 (en) | 2016-04-07 | 2022-03-23 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122008000038I1 (de) * | 1997-12-31 | 2008-11-13 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
PL354879A1 (en) | 1999-08-27 | 2004-03-08 | Inex Pharmaceuticals Corp. | Compositions for stimulating cytokine secretion and inducing an immune response |
CZ20011726A3 (cs) * | 2000-05-26 | 2002-02-13 | Pfizer Products Inc. | Způsob reakční krystalizace, který umoľňuje řídit velikost částic |
-
2002
- 2002-10-21 RU RU2004116311/04A patent/RU2004116311A/ru not_active Application Discontinuation
- 2002-10-21 AT AT02775143T patent/ATE320256T1/de not_active IP Right Cessation
- 2002-10-21 WO PCT/IB2002/004380 patent/WO2003045394A1/en active IP Right Grant
- 2002-10-21 CA CA002468705A patent/CA2468705A1/en not_active Abandoned
- 2002-10-21 AU AU2002341327A patent/AU2002341327A1/en not_active Abandoned
- 2002-10-21 KR KR10-2004-7008116A patent/KR20040066140A/ko not_active Application Discontinuation
- 2002-10-21 ES ES02775143T patent/ES2258652T3/es not_active Expired - Lifetime
- 2002-10-21 BR BRPI0214559-6A patent/BR0214559A/pt not_active IP Right Cessation
- 2002-10-21 EP EP02775143A patent/EP1461040B1/en not_active Expired - Lifetime
- 2002-10-21 MX MXPA04003192A patent/MXPA04003192A/es active IP Right Grant
- 2002-10-21 DE DE60209929T patent/DE60209929T2/de not_active Expired - Fee Related
- 2002-10-21 IL IL16132602A patent/IL161326A0/xx unknown
- 2002-10-21 PL PL02374325A patent/PL374325A1/xx not_active Application Discontinuation
- 2002-10-21 CN CNA028229304A patent/CN1589148A/zh active Pending
- 2002-10-21 JP JP2003546896A patent/JP4196829B2/ja not_active Expired - Fee Related
- 2002-11-13 DO DO2002000512A patent/DOP2002000512A/es unknown
- 2002-11-22 GT GT200200236A patent/GT200200236A/es unknown
- 2002-11-25 TW TW091134190A patent/TW200300345A/zh unknown
- 2002-11-25 PE PE2002001130A patent/PE20030738A1/es not_active Application Discontinuation
- 2002-11-26 UY UY27548A patent/UY27548A1/es not_active Application Discontinuation
- 2002-11-27 AR ARP020104558A patent/AR037677A1/es unknown
- 2002-11-27 US US10/305,845 patent/US6794388B2/en not_active Expired - Fee Related
- 2002-11-27 HN HN2002000332A patent/HN2002000332A/es unknown
- 2002-11-28 SV SV2002001413A patent/SV2004001413A/es not_active Application Discontinuation
- 2002-11-29 PA PA20028559401A patent/PA8559401A1/es unknown
-
2004
- 2004-04-07 ZA ZA200402720A patent/ZA200402720B/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2527970C2 (ru) * | 2008-12-11 | 2014-09-10 | Селл Терапьютикс,Инк. | Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена |
Also Published As
Publication number | Publication date |
---|---|
UY27548A1 (es) | 2003-06-30 |
JP4196829B2 (ja) | 2008-12-17 |
AR037677A1 (es) | 2004-12-01 |
MXPA04003192A (es) | 2004-07-27 |
WO2003045394A1 (en) | 2003-06-05 |
AU2002341327A1 (en) | 2003-06-10 |
EP1461040B1 (en) | 2006-03-15 |
US6794388B2 (en) | 2004-09-21 |
JP2005513032A (ja) | 2005-05-12 |
PA8559401A1 (es) | 2004-02-07 |
KR20040066140A (ko) | 2004-07-23 |
ES2258652T3 (es) | 2006-09-01 |
PL374325A1 (en) | 2005-10-17 |
ZA200402720B (en) | 2005-05-18 |
GT200200236A (es) | 2003-06-25 |
EP1461040A1 (en) | 2004-09-29 |
BR0214559A (pt) | 2007-03-13 |
DE60209929T2 (de) | 2006-11-16 |
DE60209929D1 (de) | 2006-05-11 |
HN2002000332A (es) | 2003-12-11 |
ATE320256T1 (de) | 2006-04-15 |
SV2004001413A (es) | 2004-05-07 |
CA2468705A1 (en) | 2003-06-05 |
CN1589148A (zh) | 2005-03-02 |
US20030149044A1 (en) | 2003-08-07 |
PE20030738A1 (es) | 2003-08-28 |
DOP2002000512A (es) | 2003-05-31 |
IL161326A0 (en) | 2004-09-27 |
TW200300345A (en) | 2003-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004116311A (ru) | Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции | |
RU2092486C1 (ru) | Замещенные 3-аминохинуклидины | |
DE60318860T2 (de) | Chinucledin - derivate und deren verwendung | |
EP1551835B1 (en) | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | |
US7750011B2 (en) | Diazabicyclic aryl derivatives and their medical use | |
EP1881979B1 (en) | Novel oxadiazole derivatives and their medical use | |
EP1392307B1 (en) | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | |
EP1713487B1 (en) | Diazabicyclic aryl derivatives as cholinergic receptor modulators | |
EP1562945B1 (en) | 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof | |
JP2004533446A5 (ru) | ||
EP1713809B1 (en) | Dimeric azacyclic compounds and their use | |
US7524838B2 (en) | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | |
WO2006087306A2 (en) | Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors | |
IE892237L (en) | Derivatives of¹(1-hydroxy-2-piperidylalkyl)-indol-2-ones, 2-quinolinones,¹2-benzo£b|azapinones, benzimidazol-2-ones, and¹quinazolin-2-ones, their preparation and their application¹in therapeutics | |
JP2643274B2 (ja) | イミダゾ〔1,2−a〕ピリジン誘導体 | |
EP1390366B1 (en) | The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene | |
WO2003005998A3 (en) | A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function | |
JPWO2002060907A1 (ja) | 複素環化合物及びそれを有効成分とする脳機能改善剤 | |
US7612074B2 (en) | Diazabicyclic aryl derivatives as cholinergy ligands | |
JP4530597B2 (ja) | アザインドリジノン誘導体及びそれを有効成分とする脳機能改善剤 | |
US20040127491A1 (en) | Novel diazabicyclic biaryl derivatives | |
CN101326162A (zh) | 作为电压门控钠通道的调控剂的季铵化的α-氨基甲酰胺衍生物 | |
JPH11512444A (ja) | 新規置換アザ環式またはアザ二環式化合物 | |
JP2719063B2 (ja) | 置換3−アミノキヌクリジンp物質拮抗剤 | |
EP1656375A1 (en) | Novel quinuclidine derivatives and their pharmaceutical use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050526 |